ArticleF&S reports2026
The progestin anchor: salvaging mature oocyte yield after an unplanned six-day gonadotropin pause in oncofertility-a case report.
Article in F&S reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the retrieval of mature oocytes after an unplanned 6-day gonadotropin-free interval during oncofertility ovarian stimulation. Design: Case report. Subjects: A 22-year-old active-duty soldier with a serous borderline ovarian tumor undergoing fertility preservation after ovarian surgery. Exposure: Progestin-primed ovarian stimulation using follitropin alfa and medroxyprogesterone acetate as the sole luteinizing hormone suppressor. Gonadotropin administration was unexpectedly interrupted for 6 days because of a nondeferrable military summons, while oral medroxyprogesterone acetate was maintained. Main Outcome Measures: Metaphase II (MII) oocyte yield and maturation rate. Results: The patient had undergone ovarian surgery approximately 9 months before the reference cycle and 12 months before the index cycle. Baseline antimüllerian hormone before fertility preservation was 1.77 ng/mL. In the reference cycle, 13 follicles ≥14 mm were present on the trigger day, and 13 oocytes were retrieved, including six MII oocytes that were vitrified. At the ultrasound assessment immediately preceding the gonadotropin-free interval in the index cycle, ultrasound showed nine visible follicles, including three follicles measuring <14 mm and six follicles measuring ≥14 mm. After the 6-day interval, the trigger-day ultrasound showed seven follicles ≥14 mm in diameter, ranging from 17 to 19 mm. Estradiol remained nearly stable across the interval, from 1,612 to 1,580 pg/mL, and endogenous progesterone on the trigger day was 1.1 ng/mL. Seven oocytes were retrieved, including five MII oocytes that were vitrified. Conclusion: In this selected oncofertility patient undergoing progestin-primed ovarian stimulation, an unplanned 6-day gonadotropin-free interval did not preclude retrieval of a clinically meaningful number of mature oocytes. Continuous medroxyprogesterone acetate may represent a biologically plausible protective factor against premature luteinization, although causality cannot be inferred from a single case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.